HMG CoA reductase inhibitors (statins) for dialysis patients.

  title={HMG CoA reductase inhibitors (statins) for dialysis patients.},
  author={Sankar D. Navaneethan and Sagar Uday Nigwekar and Vlado Perkovic and David W Johnson and Jonathan C Craig and Giovanni F M Strippoli},
  journal={The Cochrane database of systematic reviews},
BACKGROUND Cardiovascular disease accounts for more than half the number of deaths among dialysis patients. The role of HMG CoA reductase inhibitors (statins) in the treatment of dyslipidaemia in dialysis patients is unclear and their safety has not been established. OBJECTIVES To assess the benefits and harms of statins in peritoneal dialysis (PD) and haemodialysis patients (HD). SEARCH STRATEGY We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled trials (CENTRAL, in… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 32 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 68 extracted citations


Publications referenced by this paper.
Showing 1-5 of 5 references

Cochrane Renal Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2008, Issue 1. Art

NS Willis, R Mitchell, GY Higgins, AC Webster, JC. Craig
Renal • 2009

Effect of lipid-lowering dietary recommendations on the nutritional intake and lipid profiles of chronic peritoneal dialysis and hemodialysis

C Morgan, B Knight, W Chang, R Rigby, J. Westhuyzen
Saltissi • 2001

Similar Papers

Loading similar papers…